Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


Complete remission with incomplete count recovery (CRi) prior to allogeneic HCT for acute myeloid leukaemia is associated with a high non-relapse mortality.

Innes AJ, Woolley P, Szydlo RM, Lozano S, Fernando F, Bansal D, Palanicawandar R, Milojkovic D, May PC, Nadal-Melsio E, Yebra-Fernandez E, Olavarria E, Apperley JF, Pavlů J.

Leukemia. 2019 Sep 2. doi: 10.1038/s41375-019-0572-z. [Epub ahead of print] No abstract available.


MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia.

Claudiani S, Gatenby A, Szydlo R, Nesr G, Abulafia AS, Palanicawandar R, Nteliopoulos G, Khorashad J, Foroni L, Apperley JF, Milojkovic D.

Haematologica. 2019 Nov;104(11):2206-2214. doi: 10.3324/haematol.2018.214809. Epub 2019 Mar 28.


Lineage switch from acute myeloid leukemia to T cell/myeloid mixed phenotype acute leukemia: First report of an adult case.

Hanley BP, Yebra-Fernandez E, Palanicawandar R, Olavarria E, Naresh KN.

Am J Hematol. 2018 Dec;93(12):E395-E397. doi: 10.1002/ajh.25283. Epub 2018 Oct 2. No abstract available.


Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignancies.

Beckerson J, Szydlo RM, Hickson M, Mactier CE, Innes AJ, Gabriel IH, Palanicawandar R, Kanfer EJ, Macdonald DH, Milojkovic D, Rahemtulla A, Chaidos A, Karadimitris A, Olavarria E, Apperley JF, Pavlu J.

Clin Nutr. 2019 Apr;38(2):738-744. doi: 10.1016/j.clnu.2018.03.008. Epub 2018 Mar 28.


E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy.

Claudiani S, Apperley JF, Gale RP, Clark R, Szydlo R, Deplano S, Palanicawandar R, Khorashad J, Foroni L, Milojkovic D.

Haematologica. 2017 Aug;102(8):e297-e299. doi: 10.3324/haematol.2017.168740. Epub 2017 May 11. No abstract available.


Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia.

Claudiani S, Apperley JF, Deplano S, Khorashad J, Foroni L, Palanicawandar R, Perry R, Milojkovic D.

Am J Hematol. 2016 Nov;91(11):E480-E481. doi: 10.1002/ajh.24495. Epub 2016 Sep 3. No abstract available.

Supplemental Content

Loading ...
Support Center